Bristol-myers squibb company BMY.US Overview Analysis
)BMY AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a low value rating but excels in dividends. If you seek stable dividends, consider holding. For value-driven investors, think about reducing positions or switching stocks.sup
BMY Current Performance
-1.55%
Bristol-myers squibb company
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to BMY
- MIRA Mira pharmaceuticals incValue -Trend 3Swing Trading 2Whale Interest 1Dividend 1See more
BMY Profile
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.